Side-by-Side Comparison

Semaglutide vs Retatrutide

Dosing, half-life, mechanism, benefits, and safety — side by side.

Semaglutide

FDA Approved

GLP-1 receptor agonist for weight loss and type 2 diabetes management

Half-Life

~7 days

Route

Dose

0.25-2.4 mg Weekly

4113.58 Da

Full Semaglutide research guide →

Retatrutide

Research

Triple GLP-1/GIP/glucagon agonist showing exceptional weight loss potential

Half-Life

4-5 days

Route

Dose

4-12mg weekly

4889.48 Da

Full Retatrutide research guide →

Quick Reference

	Semaglutide	Retatrutide
Category	N/A	N/A
Route	SC	SC
Typical Dose	0.25-2.4 mg Weekly	4-12mg weekly
Frequency	Weekly	weekly
FDA Approved	Yes	No
WADA Status	Not banned	Not banned

⏱ Pharmacokinetics

	Semaglutide	Retatrutide
Half-Life	~7 days	4-5 days
Research Status	N/A	Phase 3 Clinical Trials - Triple agonist
CAS Number	910463-68-2	2381089-83-2

Molecular

	Semaglutide	Retatrutide
Molecular Weight	4113.58	4889.48
Molecular Formula	C187H291N45O59	C69H42N6O
Sequence Length	180 aa	180 aa
Mechanism	GLP-1 receptor agonist that regulates appetite and glucose metabolism	Triple agonist (GLP-1/GIP/Glucagon) for superior metabolic health and weight loss

Key Benefits

	Semaglutide	Retatrutide
Benefits	Significant weight loss; Blood sugar control; Reduced cardiovascular risk; Appetite suppression; Improved insulin sensitivity; GLP-1 agonist; Significant weight loss; Blood sugar control.	Triple hormone pathway activation; Metabolic optimization; Enhanced fat burning; Improved insulin sensitivity; Exceptional weight loss potential; Triple agonist (GLP-1; GIP; Glucagon)

Safety & Warnings

	Semaglutide	Retatrutide
Safety Note	FDA approved for diabetes and obesity. Common side effects include nausea, vomiting, and diarrhea.	Investigational compound in Phase 3 trials. Not yet approved for clinical use.
Side Effects	Constipation; Interaction; Nausea; Diarrhea; Rare pancreatitis or thyroid risk; Interaction; GI adverse events; Discontinuation (GI)	Nausea; Vomiting; Diarrhea; Interaction; Interaction; Constipation; Rare pancreatitis/gallstones; Mild-Moderate side effect
Athlete Warning	Not WADA banned - safe for competitive athletes when used under medical supervision	Not WADA banned - investigational metabolic compound safe for competitive athletes under medical supervision

Which should you choose?

Semaglutide has FDA-approved status while Retatrutide remains a research compound — relevant if regulatory standing matters to you. Retatrutide has a longer half-life (~4-5 days) than Semaglutide (~~7 days), which can mean less frequent dosing.

Semaglutide vs Retatrutide — FAQ

Which has a longer half-life: Semaglutide or Retatrutide?

Semaglutide has a half-life of ~~7 days while Retatrutide has a half-life of ~4-5 days. A longer half-life generally means less frequent dosing and more stable levels.

Is Semaglutide or Retatrutide FDA approved?

Semaglutide is FDA approved, while Retatrutide is a research compound without FDA approval. Always research regulatory status in your jurisdiction.

Can I stack Semaglutide and Retatrutide together?

Whether Semaglutide and Retatrutide can be stacked depends on their mechanisms and receptor targets. Use the stack compatibility checker to analyze synergies and conflicts before combining any peptides.

Which is better: Semaglutide or Retatrutide?

There is no universal "better" peptide — it depends on your goal. Semaglutide is GLP-1 receptor agonist that regulates appetite and glucose metabolism. Retatrutide is Triple agonist (GLP-1/GIP/Glucagon) for superior metabolic health and weight loss. Choose based on your primary goal and research profile.

Compare any two peptides Check stack compatibility

More Comparisons

Tirzepatide vs Semaglutide

Compare side-by-side →

BPC-157 vs TB-500

Compare side-by-side →

Retatrutide vs Tirzepatide

Compare side-by-side →

Ipamorelin vs Sermorelin

Compare side-by-side →

CJC-1295 vs Sermorelin

Compare side-by-side →

MK-677 vs Ipamorelin

Compare side-by-side →

GHK-Cu vs AHK-Cu

Compare side-by-side →

Selank vs Semax

Compare side-by-side →

MOTS-c vs NAD+

Compare side-by-side →

PT-141 vs Melanotan-II

Compare side-by-side →

Tesamorelin vs CJC-1295

Compare side-by-side →

HGH vs MK-677

Compare side-by-side →

Semaglutide vs Liraglutide

Compare side-by-side →